Country Access Report
Kenya maintains a restrictive national control regime for narcotics and psychotropic substances under the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245), which broadly prohibits unauthorized possession, manufacture, trafficking and use of many classic psychedelics while preserving medical/regulated channels for legitimately recognized medicines. In practice, conventional psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are classified under the general narcotics/psychotropic controls and have no routine reimbursed medical access outside of approved clinical research; ketamine is the primary dissociative agent available within licensed medical settings and is subject to tight pharmacy/poisons controls. Reimbursement through public insurance for psychedelic therapies is effectively non‑existent; any clinical or compassionate use requires regulatory engagement with the Kenya Pharmacy and Poisons Board and is typically covered privately or funded through research/compassionate‑use mechanisms rather than national health insurance.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified as a strictly controlled psychotropic/narcotic under Kenya's national drug control framework with no authorized medical use outside of approved clinical research. The Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245) provides the statutory basis for controlling possession, trafficking and use of psychotropic substances in Kenya [1].
Compound Access
Currently classified as a strictly controlled psychotropic/narcotic under Kenya's national drug control framework with no authorized medical use outside of approved clinical research. The primary legal authority is the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245), which criminalizes unauthorized possession and trafficking of psychotropic substances [1].
Compound Access
There is no publicly available evidence of a marketing authorization for esketamine (Spravato or other esketamine products) on the Kenya Pharmacy and Poisons Board registers as of Feb 20, 2026; therefore routine clinical availability and public reimbursement are not established. The national regulator responsible for medicine registration and market authorisations is the Pharmacy and Poisons Board (PPB), which manages marketing authorisations and emergency/compassionate use pathways for unregistered medicines [1]. Where unregistered or novel therapies are considered, approval must be sought from the PPB (for example, the PPB has evaluated emergency/compassionate use proposals in recent years), but a registered, reimbursed esketamine product is not documented in Kenyan public registers. For any proposed clinical use developers or clinicians must engage directly with the PPB for approvals and for clarity on reimbursement/coverage.
Compound Access
Ketamine is a licensed medicinal agent in Kenya when used within authorised medical/anaesthetic channels but is regulated as a controlled poison and is dispensed/administered under strict pharmacy and poisons controls (Part I poisons and related controls under national law). The national statutory framework governing narcotics, psychotropic substances and poisons is the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245) together with the Pharmacy and Poisons Act and PPB regulations; Kenyan case law and regulatory enforcement have treated ketamine as a controlled/Part I poison in pharmacy prosecutions. For example, recent Kenyan court decisions reference ketamine as Part I poisons in prosecutions related to unlicensed dispensing. [1].
Clinical/medical context and access: Ketamine (typically intravenous, intramuscular or intranasal formulations depending on indication and formulation) is available for licensed indications such as anaesthesia and acute pain management within hospitals; clinicians and institutions may also pursue PPB review for compassionate or investigational/off‑label uses (for example, an institutional approval was obtained and described for IV ketamine in a severe alcohol use disorder case, where the Pharmacy and Poisons Board evaluated and authorized an emergency/compassionate use proposal subject to conditions including informed consent, adverse‑event reporting and product accountability). That institutional approval process and conditions were described in a peer‑reviewed case report and referenced PPB guidance on emergency and compassionate use. [2]; the PPB is the competent authority for such authorisations [3].
Reimbursement and payer landscape: There is no routine public insurance reimbursement pathway in Kenya for off‑label psychiatric/psychedelic uses of ketamine (e.g., repeated ketamine infusions for depression) — such uses are typically private/fee‑for‑service, research‑funded, or provided under institutional/compassionate arrangements requiring PPB oversight. The PPB has required detailed reporting and conditions where ketamine has been approved for experimental or compassionate use, and expressly clarifies that such approvals do not constitute marketing authorisations for general sale.
Compound Access
Currently classified as a strictly controlled psychotropic/narcotic under Kenya's drug control laws with no authorised medical use outside of approved clinical research. The statutory control framework is the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245). [1].
Compound Access
Currently classified as a strictly controlled psychotropic/narcotic under Kenya's drug control laws with no authorised medical use outside of approved clinical research. The controlling statute is the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245). [1].
Compound Access
Currently classified as a strictly controlled psychotropic/narcotic under Kenya's drug control and poisons laws with no authorised medical use outside of approved clinical research. The legal basis for control is the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245). There is no routine clinical access or reimbursement pathway for ibogaine in Kenya. [1].
Compound Access
Ayahuasca preparations typically contain DMT and are therefore treated under the same national controls as DMT and related psychotropic substances; there is no authorised medical or reimbursed access outside approved clinical research. The Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245) provides the legal basis for prohibition and control. [1].
Compound Access
Mescaline and mescaline‑containing cacti (e.g., peyote) fall under Kenya's psychotropic/narcotic controls and have no authorised medical or reimbursed access outside approved clinical research. The Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245) is the controlling statute. [1].
Compound Access
Phenethylamine '2C‑X' class compounds are controlled under Kenya's psychotropic/narcotic legal framework and have no authorised medical use or reimbursement outside approved clinical research. The legal authority is the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245). [1].
Last updated 2 Mar 2026. Source links come from the medical access guide.